PanDrugs2 results showed as BTCs: RAF inhibitors (e.g. vemurafenib) and MEK inhibitors (e.g. trametinib), which are FDA approved drugs, alone or in combination, for the treatment of BRAF-mutant melanoma patients. This evidence concerns the gene MAP2K7 and melanoma.